


RealRate

PHARMACEUTICAL 2017



Altimmune Inc. Rank 3 of 313





PHARMACEUTICAL 2017





Altimmune Inc. Rank 3 of 313

The relative strengths and weaknesses of Altimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimmune Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 647% points. The greatest weakness of Altimmune Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 289% points.

The company's Economic Capital Ratio, given in the ranking table, is 376%, being 793% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	222,270
Cost of Goods Sold	0
Intangible Assets	2,348
Liabilities, Current	204,838
Liabilities, Non-Current	443
Other Assets	0
Other Compr. Net Income	-1.1
Other Expenses	11,313
Other Liabilities	0
Other Net Income	221,518
Property and Equipment	121
Research and Development	4,836
Revenues	0
Selling, General and Administrative Expense	11,515

Output Variable	Value in 1000 USD
Assets	224,739
Liabilities	205,280
Expenses	27,664
Stockholders Equity	19,459
Net Income	193,854
Comprehensive Net Income	193,854
Economic Capital Ratio	376%